MedTrace Logo

Study of Atropine Therapeutic Effect on Myopic Progression

NCT05529056 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 472

Last updated 2023-02-23

No results posted yet for this study

Summary

This study is to evaluate the therapeutic effect and safety of LPTAT in children with myopia.

Conditions

  • Myopia
  • Children

Interventions

DRUG

Atropine Sulfate 01

Atropine sulfate 01 ophthalmic solution

DRUG

Atropine Sulfate 02

Atropine sulfate 02 ophthalmic solution

DRUG

Atropine Sulfate 03

Atropine sulfate 03 ophthalmic solution

DRUG

Placebo

Placebo ophthalmic solution

Sponsors & Collaborators

  • LitePharmTech Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Sei Yeul Oh · Samsung Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-25
Primary Completion
2023-06-30
Completion
2023-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05529056 on ClinicalTrials.gov